Literature DB >> 29373184

Dose-volume and radiobiological dependence on the calculation grid size in prostate VMAT planning.

James C L Chow1, Runqing Jiang2.   

Abstract

This study evaluated the effects of dose-volume and radiobiological dependence on the calculation grid size in prostate volumetric-modulated arc therapy (VMAT) planning. Ten patients with prostate cancer were selected for this retrospective treatment planning study. Prostate VMAT plans were created for the patients using the 6 MV photon beam produced by a Varian TrueBEAM linac with the calculation grid size equal to 1, 2, 2.5, 3, 4, and 5 mm. Dose-volume histograms (DVHs) of targets and organs at risk were generated for different grid sizes. We calculated the radiobiological parameters of the tumor control probability (TCP) of clinical target volume (CTV) and planning target volume (PTV), and the normal tissue complication probability (NTCP) of organs at risk (rectal wall, rectum, bladder wall, bladder, left femur, and right femur). The homogeneity, conformity, and gradient indexes of CTV and PTV were calculated for different grid sizes. The TCP of PTV was found decreasing with a rate of 0.06%/mm when the calculation grid size increased from 1 to 5 mm. On the other hand, both NTCPs of rectal wall and rectum were found decreasing with rates of 0.03%/mm and 0.05%/mm, respectively, with an increase of grid size. The homogeneity index of PTV increased with a rate of 0.57/mm of the calculation grid size, whereas the conformity index of PTV decreased with a rate of 0.0075/mm. The gradient index of PTV was found increasing with a rate equal to 0.05/mm. In prostate VMAT planning, variations of dose-volume and radiobiological parameters with calculation grid size on PTV, rectal wall, and rectum were more significant than those of CTV and other organs at risk such as bladder wall, bladder, and femurs. Results in this study are important in the treatment planning quality assurance when the calculation grid size is varied to compromise a shorter dose computing time.
Copyright © 2017 American Association of Medical Dosimetrists. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Grid size; NTCP and dose-volume histogram; Prostate VMAT; TCP; Treatment planning

Mesh:

Year:  2018        PMID: 29373184     DOI: 10.1016/j.meddos.2017.12.002

Source DB:  PubMed          Journal:  Med Dosim        ISSN: 1873-4022            Impact factor:   1.482


  5 in total

1.  Dosimetric and radiobiological comparison in head-and-neck radiotherapy using JO-IMRT and 3D-CRT.

Authors:  Duong Thanh Tai; Luong Thi Oanh; Pham Hoai Phuong; Abdelmoneim Sulieman; Fouad A Abolaban; Hiba Omer; James C L Chow
Journal:  Saudi J Biol Sci       Date:  2022-06-02       Impact factor: 4.052

2.  Dose Super-Resolution in Prostate Volumetric Modulated Arc Therapy Using Cascaded Deep Learning Networks.

Authors:  Dong-Seok Shin; Kyeong-Hyeon Kim; Sang-Won Kang; Seong-Hee Kang; Jae-Sung Kim; Tae-Ho Kim; Dong-Su Kim; Woong Cho; Tae Suk Suh; Jin-Beom Chung
Journal:  Front Oncol       Date:  2020-11-16       Impact factor: 6.244

3.  Study on the ability of 3D gamma analysis and bio-mathematical model in detecting dose changes caused by dose-calculation-grid-size (DCGS).

Authors:  Han Bai; Sijin Zhu; Xingrao Wu; Xuhong Liu; Feihu Chen; Jiawen Yan
Journal:  Radiat Oncol       Date:  2020-07-06       Impact factor: 3.481

Review 4.  Epigenetic mechanisms underlying prostate cancer radioresistance.

Authors:  Catarina Macedo-Silva; Rosaria Benedetti; Fortunato Ciardiello; Salvatore Cappabianca; Carmen Jerónimo; Lucia Altucci
Journal:  Clin Epigenetics       Date:  2021-06-08       Impact factor: 6.551

5.  Dosimetric, Radiobiological and Secondary Cancer Risk Evaluation in Head-and-Neck Three-dimensional Conformal Radiation Therapy, Intensity-Modulated Radiation Therapy, and Volumetric Modulated Arc Therapy: A Phantom Study.

Authors:  Jalil Ur Rehman; Muhammad Isa; Nisar Ahmad; Gulfam Nasar; H M Noor Ul Huda Khan Asghar; Zaheer Abbas Gilani; James C L Chow; Muhammad Afzal; Geoffrey S Ibbott
Journal:  J Med Phys       Date:  2018 Apr-Jun
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.